

Platform Expansion: Lung Cancer Diagnostic Test Update

Highlights

- ✓ Preliminary data from the Baker Institute on lung cancer diagnostic test revealed positive outcomes.
- ✓ A 5 biomarker-combination has identified above 85% Sensitivity and 90% Specificity.

Rhythm Biosciences Ltd (ASX: RHY) (“Rhythm” or the “Company”) is pleased to provide an update on its cancer diagnostics technology platform expansion program in lung cancer. As previously announced (ASX: RHY - 15 December 2022), together with the Baker Institute, Rhythm has identified a 5 biomarker combination that exhibits an effective correlation with various stages of lung cancer.

The preliminary assessment of 17 biomarkers was performed by the Baker Institute in a “research use only” feasibility immunoassay study to evaluate these blood-based biomarkers from 70 lung cancer patients and 71 healthy volunteers. This preliminary R&D has identified an important biomarker combination that can distinguish between patients with lung cancer and healthy controls, with **>85% sensitivity and >90% specificity** ($P \leq 0.00001$).

Lung cancer stages identified in this study are in the following table.

| | Lung cancer | Healthy control | Total |
|---------------|-------------|-----------------|------------|
| Median Age | 61 | 63 | |
| Male Female | 40 30 | 42 29 | |
| Stage I | 16 | | |
| Stage II | 15 | | |
| Stage III | 20 | | |
| Stage IV | 19 | | |
| Total | 70 | 71 | 141 |

The 5-year overall survival rate for Stage 1 lung cancer is approximately 68% from diagnosis, and Stage 2 is at 35%. Survival for locally advanced cancers (Stage 3) is approximately 17%, while the 5-year survival rate for Stage 4 (metastatic lung cancer) is at 3% – National Cancer Control Indicator (NCCI).

These encouraging results warrant confirmation in a larger population and justify the continuation and advancement of the project. Therefore, verification of these results would support the case for investment in a new R&D program to develop, validate, clinically evaluate the performance of the biomarkers, and translate these results into a commercially scalable, proprietary blood test to detect lung cancer early when it is most responsive to potentially curative treatments.

About Lung Cancer

Lung cancer remains the leading cause of cancer-related deaths worldwide, primarily because most people present when the stage is too advanced to offer any reasonable chance of cure.¹ The Australian Institute of Health and Welfare estimated that in 2022, 14,529 Australians were diagnosed with lung cancer, and more than 8,6064 died from the disease.² Overall, the 5-year survival rate for Lung cancer is low, at about 22%² and there is a clear need to improve the diagnostic tools for screening in detecting early-stage lung cancer.

- ENDS -

Authorisation & Additional Information

Rhythm Biosciences Ltd
ACN 619 459 335
ASX: RHY

www.rhythmbio.com

Australian Registered Address
Bio21 Molecular Science & Biotechnology Institute
30 Flemington Road
Parkville VIC 3010 Australia

T +61 3 8256 2880
E info@rhythmbio.com

Directors
Otto Buttula
Sue MacLeman
Trevor Lockett
Rachel David
Louis Panaccio

Executive Chairman
Independent Deputy Chair
Executive Director
Non-Executive Director
Non-Executive Director

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information contact us via investor@rhythmbio.com or on +61 3 8256 2880

| | |
|---|---|
| Mr. Otto Buttula Executive Chairman | Ms. Elena Deak Chief Commercial Officer |
|---|---|

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.

The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and Twitter.

References

1. Burzic A, O'dowd EL, Baldwin DR. The Future of Lung Cancer Screening: Current Challenges and Research Priorities. *Cancer Manag Res.* 2022;14(January):637-645. doi:10.2147/CMAR.S293877
2. <https://www.canceraustralia.gov.au/cancer-types/lung-cancer/statistics>